Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
April 26 2007 - 5:05PM
PR Newswire (US)
SAN DIEGO, April 26 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) will be presenting at the
Morgan Stanley Global Healthcare Conference on Wednesday, May 2,
2007 at 9:30 a.m. ET in Miami. Daniel M. Bradbury, President and
Chief Executive Officer of Amylin Pharmaceuticals, will be
providing a corporate overview. The live presentation will be
webcast, and a recording will be made available following the
event. The webcast and recording will be accessible through
Amylin's corporate website, located at http://www.amylin.com/. To
access the live webcast, please log on to Amylin's site
approximately fifteen minutes prior to the presentation to register
and download any necessary audio software. About Amylin
Pharmaceuticals Amylin Pharmaceuticals is a biopharmaceutical
company committed to improving lives through the discovery,
development and commercialization of innovative medicines. Amylin
has developed and gained approval for two first-in-class medicines
for diabetes, SYMLIN(R) (pramlintide acetate) injection and
BYETTA(R) (exenatide) injection. Amylin's research and development
activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin
is located in San Diego, California with over 1,600 employees
nationwide. For more information about Amylin visit
http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc.
CONTACT: Alice Bahner, Executive Director, Investor Relations of
Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 7272 Web site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024